
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Paulash Mohsen, vice president, primary care strategy for Pfizer, talks about changes in the pharmaceutical environment, and what industry might do to best adapt.






